Celularity Inc. (NASDAQ:CELU) Sees Significant Growth in Short Interest

Celularity Inc. (NASDAQ:CELU) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 415,800 shares, a growth of 7.1% from the March 15th total of 388,300 shares. Based on an average daily volume of 253,600 shares, the short-interest ratio is currently 1.6 days. Approximately 3.9% of the company’s stock are short sold.

Celularity Stock Up 2.2 %

Shares of NASDAQ:CELU opened at $4.20 on Tuesday. Celularity has a fifty-two week low of $1.59 and a fifty-two week high of $8.90. The firm has a 50-day simple moving average of $4.83 and a 200 day simple moving average of $3.26.

Institutional Investors Weigh In On Celularity

A number of institutional investors have recently modified their holdings of the business. IPG Investment Advisors LLC lifted its stake in Celularity by 97.9% during the third quarter. IPG Investment Advisors LLC now owns 171,695 shares of the company’s stock valued at $38,000 after purchasing an additional 84,928 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new stake in shares of Celularity in the 2nd quarter valued at approximately $125,000. State Street Corp acquired a new position in Celularity in the 2nd quarter valued at approximately $697,000. Cubist Systematic Strategies LLC acquired a new position in Celularity in the 2nd quarter valued at approximately $48,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Celularity during the 2nd quarter worth $99,000. Institutional investors own 19.02% of the company’s stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.